miR-16: expanding the range of molecular targets in mesothelioma
Mené sur 26 patients atteints d'un mésothéliome pleural malin récidivant, cet essai de phase I évalue l'activité antitumorale, la dose maximale tolérée, l'efficacité, du point de vue du taux de réponse objective, et la toxicité d'un traitement à base de minicellules chargées en micro-ARNs miR-16 et ciblant EGFR (TargomiRs)
Malignant mesothelioma is a cancer caused by exposure to asbestos. It has a devastating prognosis, and its incidence has increased substantially in high-income countries during the past three decades. Systemic therapy comprising cisplatin and pemetrexed remains the only approved standard of care, a therapeutic plateau that has endured for more than 10 years. New, effective therapies based on an understanding of the underlying biology are clearly needed. By contrast with many other cancers, including lung cancer and melanoma, somatic mutations in oncogenic kinases have not been identified in the genomic landscape of mesotheliomas.
The Lancet Oncology , commentaire, 2016